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Highly Active Antiretroviral Therapy (HAART) for the 
treatment for human immunodeficiency virus (HIV) includes 
using different classes of anti-HIV agents, including nucleoside 
reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) along with protease inhibitors 
(Agarwal, 2008). 2′,3′-Dideoxynucleoside (ddN) analogs are 
similar to naturally occurring nucleosides, but they cannot be 
used for the synthesis of new DNA as they lack the 3′-hydroxyl 
group. These agents act as nucleoside reverse transcriptase 
inhibitors (NRTIs) and thereby cause DNA chain termination. 
NRTIs have shown severe adverse effects, mitochondrial 
toxicity, and resistance to multi-drug resistant HIV.1-4 
Furthermore, nucleoside analogs are polar in nature and have 
limited cellular uptake. Novel anti-HIV agents are urgently 
needed with a better safety and resistance profile for the 
prevention and treatment of HIV infection.  
Prevention of HIV transmission to women  is essential to 
avoid transmission of the virus to the newborn. Currently there 
are no vaccines developed to provide protection against HIV. 
Thus, it is a necessity to develop additional safe, effective 
treatment and preventative strategies. 
______________________________________________
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Microbicidal agents are agents which are topically applied to 
the vagina or rectum prevent the transmission of sexually 
transmitted organisms., Microbicides which are focused on the 
prevention of HIV transmissiontarget vaginal, cervical or rectal 
mucosa and may act via several mechanisms, such as the non-
specific direct inactivation of the virus.6 Currently known 
microbicides in development, such as UC-781 
(thiocarboxanilide), TMC-120 (dapivirine), MIV-150, and 
tenofovir, act specifically via a single mechanism of the 
inhibition of reverse transcriptase enzyme.7 Thus, they have the 
potential to induce viral resistance and are less effective against 
cell-associated virus. Developing new anti-HIV microbicides that 
are multifunctional anti-HIV agents is urgently needed to reduce 
the incidence of drug resistance. Furthermore, the lipophilic 
microbicides could bind tightly or irreversibly to the HIV 
envelope, leading to inactivation of cell-free, or cell-associated 
virus or both resulting in a significant decrease in virus 
transmission. 
Furthermore, there have been several reports on lipids acting 
as antiviral and antibacterial agents.8 The medium length chain 
saturated fatty acids are one of those agents that inhibit 
enveloped viruses like HIV and herpes simplex virus type 1 
(HSV-1).9 Microbicidal hydrogels of these fatty acids have been 
developed and evaluated, and they possibly act by disrupting the 
viral lipid membrane.9 HIV-1 replication is inhibited by 
heteroatom substituted myristic acid analogs without showing 
any significant cellular toxicity. Myristoylated HIV proteins 
include PR160gag-pol, Pr55gag, p17gag, and p27nef. Myristic acid 
analogs inhibit the N-myristoyl transferase (NMT) that catalyzes 
the N-myristoylation of HIV proteins.10 2-Methoxydodecanoic 
acid, 4-oxatetradecanoic acid, and 12-thioethyldodecanoic acid 
have shown to reduce HIV-1 replication in acutely infected 
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A number of 5′-O-dicarboxylic fatty acyl monoester derivatives of 3'-azido-3'-deoxythymidine 
(zidovudine, AZT), 2',3'-didehydro-2',3'-dideoxythymidine (stavudine, d4T), and 3'-fluoro-3'-
deoxythymidine (alovudine, FLT) were synthesized to improve the lipophilicity and potentially 
the cellular delivery of parent polar 2′,3′-dideoxynucleoside (ddN) analogs. The compounds 
were evaluated for their anti-HIV activity. Three different fatty acids with varying chain length 
of suberic acid (octanedioic acid), sebacic acid (decanedioic acid), and dodecanedioic acid were 
used for the conjugation with the nucleosides. The compounds were evaluated for anti-HIV 
activity and cytotoxicity. All dicarboxylic ester conjugates of nucleosides exhibited significantly 
higher anti-HIV activity than that of the corresponding parent nucleoside analogs. Among all the 
tested conjugates, 5′-O-suberate derivative of AZT (EC50 = 0.10 nM) was found to be the most 
potent compound and showed 80-fold higher anti-HIV activity than AZT without any significant 
toxicity (TC50 > 500 nM). 
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Scheme 1. Synthesis of 5′–mono-substituted fatty acyl ester nucleoside conjugates of FLT, AZT, and d4T (1-6). 
 
T-lymphocytes.11 For example, 12-thioethyldodecanoic acid 
derivative was moderately active (EC50 = 9.4 µM) against HIV-
infected T4 lymphocytes. 
Several studies have demonstrated the use of lipids as active 
intravaginal microbicide agents to protect against various 
sexually transmitted infections (STIs).8-10 When lipid-associated 
drugs are administered subcutaneously, they are usually 
distributed throughout the lymphoid system with improved 
stability, and the drug can be delivered at higher concentrations.12 
This is a major advantage since HIV is hidden in the lymphatic 
system not accessible by many commercially available polar anti-
HIV nucleosides. 
Thus, designing lipophilic anti-HIV nucleosides for 
developing anti-HIV agents or anti-HIV microbicides is a subject 
of major interest. The most predominant approach to this strategy 
is the esterification strategy between nucleosides and fatty acids. 
The in vitro chemical stability of ester conjugates helps to 
produce formulations with adequate shelf lives. The esters also 
act as the substrates for esterase enzyme and, therefore, are labile 
in vivo.13 The 5′-O-hydroxyl esterification of the anti-HIV 
nucleosides also provides a viable approach to increase cellular 
delivery of polar nucleosides. We have previously shown that 
fatty acyl monocarboxylic ester derivatives of 3'-azido-3'-
deoxythymidine (zidovudine, AZT),14,15 3'-fluoro-3'-
deoxythymidine (FLT),16 (-)-2',3'-dideoxy-3'-thiacytidine 
(3TC),17 5-fluoro-(-)-2',3'-dideoxy-3'-thiacytidine (FTC),18 and 
2',3'-didehydro-2',3'-dideoxythymidine (stavudine, d4T)19 with 
enhanced anti-HIV activity against CXC4-tropic, CCR5-tropic 
cell-associated, and/or multi-drug resistant strains of virus. The 
fatty acid substitution with FTC and 3TC showed a significant 
increase in their cellular uptake in comparison to their parent 
nucleosides.17,18 
Herein, we report the synthesis and evaluation of novel 5′-O-
fatty acyl ester derivatives of AZT, d4T, and FLT using 
dicarboxylic fatty acids. As shown before for other conjugates, 
fatty acids were expected to improve the lipophilicty of polar 
nucleoside analogs and cellular uptake and to generate lipophilic 
agents with higher anti-HIV activity. Dicarboxylic acids instead 
of monocarboxylic fatty acids were selected to generate more 
amphipathic property in the structure of conjugates due to the 
presence of additional polar free carboxylic acid.  
The synthesis of seven mono-substituted 5′-O-(fatty 
acyl)esters of nucleosides is shown in Scheme 1. Three 
nucleosides, FLT, AZT, and d4T, and three different dicarboxylic 
fatty acids were used for esterification. The conjugates were 
synthesized by reacting nucleosides and dicarboxylic fatty acids 
in N,N-dimethylformamide (DMF) in the presence of 2-(1H-
benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU), 1-hydroxybenzotriazole (HOBt) 
and diisopropylcarbodiimide (DIC) as coupling reagents and 
N,N-diisopropylethylamine (DIPEA) as a base. The reaction 
mixtures were stirred at room temperature overnight. The final 
products were purified by HPLC on C-18 column using water 
and acetonitrile as the solvent system in order to achieve more 
than 95% purity. The chemical structures of the final products 
were characterized by nuclear magnetic resonance spectrometry 
(1H NMR and 13C NMR), and were confirmed by a high–
resolution time-of-flight electrospray mass spectrometer. 
All the synthesized conjugates were evaluated for their 
inhibitory activity of HIV–1 (subtype B, US/92/727) replication 
in human peripheral blood mononuclear (PBMC) cells.20 Table 1 
illustrates the anti-HIV-1 activity (EC50) and cytotoxicity (TC50) 
of the nucleoside ester conjugates compared with their 
corresponding parent nucleosides. No cytotoxicity was observed 
up to the highest tested concentration for both the parent 
nucleosides and the synthesized conjugates (TC50 > 500 nM) (1-
7). 
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Table 1. Anti-HIV activity of dicarboxylic acid ester conjugates of nucleoside conjugates (1-7). 
PBMC/HIV-1US/92/727  
Compd. Chemical Name 
EC50 (nM)a TC50 (nM)b TIc 
Log Pd 
 
    
 
AZT 3'-azido-2',3'-dideoxythymidine 8.00 >1000 >125 -0.24e 
FLT 3'-fluoro-2',3'-deoxythymidine 2.00 >500 >250 -0.41 
d4T 2',3'-didehydro-2',3'-dideoxythymidine 90.0 >500 >5.6 -0.34 
 
    
 
1 8-[(3′-azido-2′,3′-dideoxythymidinyl)-5′-yl]octandioate 0.10 >500 >5000 1.97e 
2 10-[(3′-azido-2′,3′-dideoxythymidinyl)-5′-yl]decandioate 0.31 >500 >1613 3.03e 
3 12-[(3′-azido-2′,3′-dideoxythymidinyl)-5′-yl]dodecandioate 0.33 >500 >1516 4.09e 
 
    
 
4 10-[5′-O-(3′-fluoro-2′,3′-dideoxythymidinyl)]decandioate 0.26 >500 >1923 1.99 
5 12-[5′-O-(3′-fluoro-2′,3′-dideoxythymidinyl)]dodecandioate 0.25 >500 >2000 2.83 
 
    
 
6 10-[(2',3'-didehydro-2',3'-dideoxythymidine)-5′-yl]decandioate 1.98 >500 >253 2.06 
7 12-[(2',3'-didehydro-2',3'-dideoxythymidine)-5′-yl]dodecandioate 18.30 >500 >27 2.90 
 
     
 
aEC50 (50% effective concentration), All the assays were carried out in triplicate (n = 3); bTC50 (50% toxic concentration), All 
the assays were carried out in triplicate (n = 3); cTherapeutic index(TC50/EC50); dCalculated Partition coefficient by ChemDraw 
Ultra 12.0; eCLogP calculated by ChemDraw Ultra 12.0. 
 
The AZT conjugates (1-3, EC50 = 0.1-0.3 nM) exhibited 
consistently higher anti-HIV activity than that of AZT (EC50 = 
8.0 nM). For example, octandioate (suberate) ester derivative of 
AZT (1, EC50 = 0.1 nM) showed 80 times higher anti-HIV 
activity than the parent nucleoside. AZT conjugates having 
longer chain fatty acids also showed enhancement in anti-HIV 
activity than AZT while the ratio of improvement was less than 
that of compound 1. The decandioate ester of AZT (2, EC50 = 
0.31 nM) was 26-fold more potent than that of AZT. The activity 
of dodecandioate ester of AZT (3) was 24 times higher when 
compared to AZT. Among the AZT conjugates, AZT-suberate 
conjugate (1) showed the highest anti-HIV activity. These data 
suggest that conjugation of AZT with dicarboxylic acids 
significantly enhances the anti-HIV activity with higher potency 
seen in conjugates with shorter chain length. 
Similarly, dicarboxylic ester conjugates of d4T (6 and 7, EC50 
= 1.98-18.3 nM) showed better anti-HIV activity from that of 
d4T (EC50 = 90 nM) in the PBMC assay against HIV–1US/92/727. 
The decanedioate ester of d4T (6, EC50 = 1.98 nM) exhibited 45 
times more anti-HIV activity than d4T. The dodecandioate ester 
of d4T (7, EC50 = 18.3 nM) showed 5 times higher anti-HIV 
activity when compared to that of its parent nucleoside. These 
results indicate that the anti-HIV activity of the carboxylic esters 
of nucleoside depends on the chain length of the carboxylic acid, 
and shorter length dicarboxylate monoester conjugates are more 
potent. 
A similar trend was observed for FLT ester conjugates 
compared to the parent nucleoside. Amongst all the FLT 
conjugates (EC50 = 0.25-0.26 nM), the decanedioate ester of FLT 
(4, EC50 = 0.26 nM) and dodecanedioate ester of FLT (5, EC50 = 
0.25 nM) showed an 8-fold  increase in anti-HIV activity when 
compared to FLT (EC50 = 2 nM), but the difference in anti-HIV 
activity between the  two conjugates was not significant. 
There was a significant increase in the therapeutic index of 
AZT and FLT derivatives when compared to that of the 
respective parent nucleosides. The increased therapeutic index 
indicates synergistic effect of conjugation of dicarboxylic acids 
with ddNs. Among all the synthesized dicarboxylic acid ester 
derivatives of AZT, FLT, and d4T, the decandioate monoester 
conjugate of AZT (1) showed the highest anti-HIV activity. 
This study indicates that NRTIs when in conjugation with 
long chain dicarboxylic acids exhibit higher anti-HIV activity 
possibly due to the improved lipophilicity thereby increasing the 
cellular uptake of NRTIs. As shown by calculated partition 
coefficient values (Table 1), the ester conjugates were more 
lipophilic that their parent analogs. We have shown previously 
for other fatty acyl derivatives of nucleosides that the highly 
lipophilic conjugates could have higher cellular uptake 
contributing to their improved anti-HIV activity.17,18However, for 
dicarboxylic monoester conjugates, an appropriate lipophilicty is 
required for an optimal anti-HIV activity since highly lipophilic 
conjugates with longer chain length were less potent than those 
with shorter chain length. We have previously shown higher 
cellular uptake and the intracellular hydrolysis of several fatty 
acyl ester derivatives of 3TC, d4T, and FTC.17-19 Similarly, it is 
expected that when the conjugate esters enter the cells, they 
undergo intracellular hydrolysis by esterases and release the anti-
HIV nucleosides and fatty acids targeting different stages of the 
HIV life cycle possibly contributing to enhanced anti-HIV 
activity. Nucleoside and fatty acid analogs are known to target 
the reverse transcriptase and the NMT enzymes. More 
mechanistic studies are required to determine the exact 
mechanism of activity of the ester conjugates of the nucleosides. 
In conclusion, several lipophilic 5′-O-fatty acyl dicarboxylic 
monoester derivatives of the nucleoside reverse transcriptase 
inhibitors, AZT, FLT, and d4T were synthesized and evaluated 
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for their anti-HIV activity. The fatty acid substitution at the 5′-
O-position enhanced the lipophilicity of the anti-HIV nucleoside 
analogs. All conjugates exhibited  higher anti-HIV activity when 
compared to their parent nucleosides. The improved viral 
inhibition by the AZT, d4T, and FLT fatty acyl derivatives versus 
the parent  nucleoside is presumably due to the enhanced cellular 
uptake of the lipophilic conjugates. These conjugates have the 
potential to be used as potent anti-HIV agents and/or lipophilic 
anti-HIV microbicides after further optimization. 
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